A 52-year-old man with a 10-year history of chronic myeloid leukemia (CML) in chronic phase, well-controlled on imatinib, presents with sudden onset fever, bone pain, and bleeding gums. Hb 8.9 g/dL, WBC 185,000/μL (85% blasts), platelets 32,000/μL. Peripheral blood smear shows numerous myeloblasts with Auer rods. What is the most appropriate immediate next step?

Explanation

## Clinical Scenario: CML Blast Crisis This patient has undergone **transformation from chronic phase to acute phase (blast crisis)**, evidenced by: - Sudden clinical deterioration - >80% blasts on smear - **Auer rods** (pathognomonic for acute leukemia) - Cytopenias and bleeding ## Why Cytochemistry and Flow Cytometry Are Critical **Key Point:** Blast crisis in CML can differentiate into **myeloid (AML-like)** or **lymphoid (ALL-like)** phenotype. The lineage and BCR-ABL1 mutation status **determine treatment strategy and prognosis**. ### Diagnostic Workup for CML Blast Crisis | Test | Information Provided | Clinical Impact | |------|----------------------|------------------| | **MPO (Myeloperoxidase)** | Confirms myeloid vs. lymphoid differentiation | Positive = AML-like; negative = ALL-like | | **PAS (Periodic Acid-Schiff)** | Glycogen content; helps lineage determination | Positive in ALL-like; negative in AML-like | | **Flow Cytometry** | Immunophenotype (CD13, CD33, CD19, CD10, etc.) | Definitive lineage assignment | | **BCR-ABL1 Mutation Analysis** | Identifies imatinib resistance mechanism | Guides choice of TKI (dasatinib, nilotinib, ponatinib) | **High-Yield:** Auer rods indicate **myeloid differentiation** (AML-like blast crisis), but confirmation and mutation testing are essential before treatment escalation. ## Why This Is the Next Step 1. **Lineage determination** affects chemotherapy regimen (AML-like → daunorubicin + cytarabine; ALL-like → ALL-type induction) 2. **BCR-ABL1 mutations** (especially T315I) predict TKI resistance and may require ponatinib 3. **Flow cytometry** is rapid (24–48 hours) and guides immediate therapy 4. Proceeding without mutation data risks selecting an ineffective TKI **Clinical Pearl:** Auer rods in a CML patient = myeloid blast crisis until proven otherwise, but cytochemistry and flow confirm this and rule out other acute leukemias that may mimic blast crisis. [cite:Harrison 21e Ch 103]